AbbVie’s Humira Succession Plan Begins Taking Shape With Skyrizi US Approval
Executive Summary
Central to AbbVie’s plans to endure biosimilar erosion to Humira, Skyrizi gets US approval in psoriasis, with approval of upadacitinib expected in RA this year.
You may also be interested in...
J&J’s Gorsky Hails Strong Performance By Immunology Therapies Tremfya, Stelara
A strong fourth quarter and full-year 2019 performance by J&J was driven by significant sales growth for Tremfya and Stelara. CFO Wolk said a $4bn opioids settlement remains on track.
AbbVie’s Skyrizi Tops Novartis’s Cosentyx In Psoriasis Contest
A Phase III clinical trial comparing AbbVie's Skyrizi with Novartis's IL-17 agonist Cosentyx showed the former's superiority in adults with moderate-to-severe plaque psoriasis.
2019 Drug Launches: New Specialty And Rare Disease Blockbusters Take Shape
Novartis' Zolgensma and Pfizer's Vyndaqel were two of the early commercial standouts in 2019, on a likely blockbuster trajectory, while AbbVie's Skyrizi is poised to be fierce competitor in psoriasis.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports